HIV treatment cascade among people who inject drugs in Ukraine.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
08
2020
accepted:
10
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
23
3
2021
Statut:
epublish
Résumé
The HIV treatment cascade is an effective tool to track progress and gaps in the HIV response among key populations. People who inject drugs (PWID) remain the most affected key population in Ukraine with HIV prevalence of 22% in 2015. We performed secondary analysis of the 2017 Integrated Bio-Behavioral Surveillance (IBBS) survey data to construct the HIV treatment cascade for PWID and identify correlates of each indicator achievement. The biggest gap in the cascade was found in the first "90", HIV status awareness: only 58% [95% CI: 56%-61%] of HIV-positive PWID reported being aware of their HIV-positive status. Almost 70% [67%-72%] of all HIV-infected PWID who were aware of their status reported that they currently received antiretroviral therapy (ART). Almost three quarters (74% [71%-77%]) of all HIV-infected PWID on ART were virally suppressed. Access to harm reduction services in the past 12 months and lifetime receipt of opioid agonist treatment (OAT) had the strongest association with HIV status awareness. Additionally, OAT patients who were aware of HIV-positive status had 1.7 [1.2-2.3] times the odds of receiving ART. Being on ART for the last 6 months or longer increased odds to be virally suppressed; in contrast, missed recent doses of ART significantly decreased the odds of suppression. The HIV treatment cascade analysis for PWID in Ukraine revealed substantial gaps at each step and identified factors contributing to achievement of the outcomes. More intensive harm reduction outreach along with targeted case finding could help to fill the HIV awareness gap among PWID in Ukraine. Scale up of OAT and community-level linkage to care and ART adherence interventions are viable strategies to improve ART coverage and viral suppression among PWID.
Identifiants
pubmed: 33382768
doi: 10.1371/journal.pone.0244572
pii: PONE-D-20-24973
pmc: PMC7775055
doi:
Substances chimiques
Analgesics, Opioid
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244572Subventions
Organisme : PEPFAR
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
Drug Alcohol Rev. 2017 May;36(3):295-304
pubmed: 27242102
PLoS Med. 2017 Apr 4;14(4):e1002253
pubmed: 28376085
PLoS One. 2017 May 1;12(5):e0176914
pubmed: 28459881
J Int Assoc Provid AIDS Care. 2017 Mar/Apr;16(2):125-132
pubmed: 28090799
Int J STD AIDS. 2016 Jan;27(1):5-12
pubmed: 25907348
Open AIDS J. 2012;6:77-82
pubmed: 23049656
J Virol Methods. 2009 Dec;162(1-2):218-22
pubmed: 19729037
Int J STD AIDS. 2018 Nov;29(13):1337-1344
pubmed: 30049259
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e29-35
pubmed: 22395671
PLoS One. 2014 Dec 26;9(12):e115277
pubmed: 25541682
Curr Opin HIV AIDS. 2015 Nov;10(6):420-9
pubmed: 26352393
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):393-9
pubmed: 22134149
Sociol Methodol. 2011 Aug 1;41(1):355-366
pubmed: 22228916
J Epidemiol Community Health. 2005 Dec;59(12):1022-8
pubmed: 16286487
J Urban Health. 2003 Dec;80(4):667-75
pubmed: 14709714
J Int AIDS Soc. 2019 Jun;22(6):e25330
pubmed: 31245917
AIDS Care. 2014;26(7):835-41
pubmed: 24283220
J Urban Health. 2006 Nov;83(6 Suppl):i1-5
pubmed: 17058119
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794581
AIDS Behav. 2019 Aug;23(8):2101-2108
pubmed: 30600453
J R Stat Soc Ser A Stat Soc. 2015 Jan;178(1):241-269
pubmed: 27226702
Harm Reduct J. 2016 Jun 21;13(1):21
pubmed: 27324253
Lancet. 2010 Jul 31;376(9738):355-66
pubmed: 20650513
Lancet Infect Dis. 2010 Jul;10(7):464-9
pubmed: 20610328
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29356365
Addiction. 2015 Jan;110 Suppl 1:40-50
pubmed: 25533863
Infect Dis Clin North Am. 2000 Dec;14(4):809-25, v-vi
pubmed: 11144640
AIDS. 2013 Oct 23;27(16):2559-66
pubmed: 23770493
AIDS Behav. 2005 Dec;9(4):387-402
pubmed: 16235135
Ukr Biochem J. 2016 Mar-Apr;88(2):45-55
pubmed: 29227602
AIDS. 2005 May;19 Suppl 2:S67-72
pubmed: 15930843
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):288-295
pubmed: 30312275
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e110-7
pubmed: 24091692
BMC Public Health. 2014 Jul 21;14:735
pubmed: 25042697
AIDS. 2016 Mar 27;30(6):925-32
pubmed: 26636927
Lancet. 2018 Sep 1;392(10149):747-759
pubmed: 30191830
Clin Infect Dis. 2016 Oct 15;63(8):1094-1104
pubmed: 27343545